No Increased Breast Cancer Risk With Menopausal Estrogen in BRCA CarriersNo Increased Breast Cancer Risk With Menopausal Estrogen in BRCA Carriers
(MedPage Today) — SAN ANTONIO — Menopausal hormone therapy (MHT) did not increase breast cancer risk in women with BRCA mutations, according to a study reported here.
In fact, women who used estrogen-only MHT had a significantly lower risk…
How Were GLP-1 Drugs and Bone Health Linked?How Were GLP-1 Drugs and Bone Health Linked?
(MedPage Today) — You passed medical training, now see if you can pass our weekly quiz (MedPage Today) — You passed medical training, now see if you can pass our weekly quiz
Ozempic may offer a surprising bonus benefit for brain healthOzempic may offer a surprising bonus benefit for brain health
A new analysis suggests that people with type 2 diabetes who use GLP-1 medications like Ozempic, Trulicity or Victoza may be less likely to develop epilepsy than those taking DPP-4 inhibitors. Semaglutide showed the strongest connection to lowered risk. Researchers caution that the findings show an association, not proof of cause and effect. More rigorous Read More
One GLP-1 Drug May Be Better Than Rivals for Glaucoma RiskOne GLP-1 Drug May Be Better Than Rivals for Glaucoma Risk
(MedPage Today) — Use of the dual GIP/GLP-1 drug tirzepatide (Mounjaro, Zepbound) was associated with a significantly reduced risk of glaucoma compared with GLP-1 drugs among patients with type 2 diabetes, a large retrospective cohort study suggested… (MedPage Today) — Use of the dual GIP/GLP-1 drug tirzepatide (Mounjaro, Zepbound) was associated with a significantly Read More
Risk-Based Screening Works as Well as Yearly Checks After 40 in Finding Breast CancersRisk-Based Screening Works as Well as Yearly Checks After 40 in Finding Breast Cancers
A study of more than 45,000 women found that screening women according to their level of risk was as effective in detecting tumors as the one-size-fits-most screening currently recommended.
Study Makes the Case for Replacing Annual Breast Cancer ScreeningStudy Makes the Case for Replacing Annual Breast Cancer Screening
(MedPage Today) — SAN ANTONIO — Risk-based breast cancer screening proved noninferior for detecting clinically significant tumors in a randomized trial, though outside experts raised concerns and a major medical group said the findings do not…
More Support for Omitting Lymph Node Biopsy in Low-Risk Early Breast CancerMore Support for Omitting Lymph Node Biopsy in Low-Risk Early Breast Cancer
(MedPage Today) — SAN ANTONIO — Many patients with early breast cancer can safely skip sentinel lymph node biopsy (SLNB), results of a large Dutch study suggested.
After 5 years, the regional recurrence-free survival (RRFS) rate was 96.6…
Pre-Op MRI Shows ‘No Clinical Benefit’ in Early Breast CancerPre-Op MRI Shows ‘No Clinical Benefit’ in Early Breast Cancer
(MedPage Today) — SAN ANTONIO — Preoperative MRI for staging patients with early, hormone receptor (HR)-negative breast cancer didn’t result in improved oncologic outcomes or improved clinical care, according to a phase III study presented…
Menopausal hormone therapy may not pose breast cancer risk for women with BRCA mutations, analysis suggestsMenopausal hormone therapy may not pose breast cancer risk for women with BRCA mutations, analysis suggests
Using menopausal hormone therapy (MHT) was not associated with an increased risk of breast cancer in women with inherited mutations in the BRCA1 or BRCA2 genes, according to the results of a matched prospective analysis presented at the San Antonio Breast Cancer Symposium (SABCS), held December 9–12, 2025.
Mobile health tool may improve quality of life for adolescent and young adult breast cancer survivorsMobile health tool may improve quality of life for adolescent and young adult breast cancer survivors
A mobile health (mHealth) intervention for adolescent and young adult breast cancer survivors that offered tailored support by monitoring electronic patient-reported outcomes (ePROs) significantly improved quality of life and symptoms related to vaginal and arm problems, according to results from a randomized clinical trial presented at the San Antonio Breast Cancer Symposium (SABCS), held December 9–12, 2025.